The fastest-growing and largest of the 20 sized Pharmaceuticals markets in Africa, 2023 to 2033, with active clinical trials.
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Biosimilars | $554 Mn | $5.8 Bn | 26.4% | 25 |
| 2 | Cell Based Immunotherapy | $249 Mn | $2.2 Bn | 24.5% | 353 |
| 3 | Cannabidiol (CBD) | $331 Mn | $1.8 Bn | 18.3% | 7 |
| 4 | Cannabis | $509 Mn | $2.1 Bn | 15% | 5 |
| 5 | Atopic Dermatitis Drugs | $168 Mn | $608 Mn | 13.7% | 5 |
| 6 | Oncology/Cancer Drugs | $2.7 Bn | $6.8 Bn | 9.9% | 376 |
| 7 | Anti-Aging | $1.3 Bn | $3.3 Bn | 9.6% | 15 |
| 8 | Diabetes Management | $1.2 Bn | $2.7 Bn | 8.6% | 81 |
| 9 | Alzheimer Drugs | $75 Mn | $167 Mn | 8.3% | 1 |
| 10 | Contraceptives Drugs | $378 Mn | $839 Mn | 8.3% | 6 |
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Oncology/Cancer Drugs | $2.7 Bn | $6.8 Bn | 9.9% | 376 |
| 2 | Anti-Aging | $1.3 Bn | $3.3 Bn | 9.6% | 15 |
| 3 | Diabetes Management | $1.2 Bn | $2.7 Bn | 8.6% | 81 |
| 4 | Gastrointestinal Drugs | $810 Mn | $1.5 Bn | 6.1% | 223 |
| 5 | Asthma & COPD Drugs | $743 Mn | $1.3 Bn | 5.5% | 50 |
| 6 | Biosimilars | $554 Mn | $5.8 Bn | 26.4% | 25 |
| 7 | Cannabis | $509 Mn | $2.1 Bn | 15% | 5 |
| 8 | HIV Drugs | $450 Mn | $910 Mn | 7.3% | 142 |
| 9 | Contraceptives Drugs | $378 Mn | $839 Mn | 8.3% | 6 |
| 10 | Cancer Supportive Care Drugs | $372 Mn | $679 Mn | 6.2% | 77 |
2033 values are projected from the 2023 size and the CAGR. Each market name opens its report. Active trials: recruiting, about to start or running, in Egypt, South Africa, Kenya.
Biosimilars grows fastest, at 26.4% a year from 2023 to 2033, ahead of Cell Based Immunotherapy (24.5%).
Oncology/Cancer Drugs is the largest, worth about $2.7 Bn in 2023 and $6.8 Bn by 2033 (projected).
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide.